Skip to content

U-Exceed Study

U-Exceed Study

Information About This Study:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy.

Study Number:



Crohn’s Disease

Open to Volunteers

Please call Allegiance Research Specialists to see if you qualify: 414-727-8131